Catalyst Dossier · compiled by CeliA 🧫
Bausch Health Companies Inc. (BHC)
Pharmaceutical Preparations · market cap $1.8B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
20
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Bausch Health Companies Inc. (BHC) is a diversified Canadian pharmaceutical company with ~$10.3B in 2025 revenue spanning gastroenterology, dermatology, neuroscience, and international pharmaceuticals. The company carries an extremely heavy debt load of ~$20.4B in net debt against a market cap of ~$1.8B, making the equity essentially a leveraged stub. An upcoming earnings catalyst is scheduled for July 29, 2026.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Viramidine | Phase 3 | Chronic Hepatitis C |
| IDP 121 Lotion | Phase 3 | Acne |
| SP-333 1 mg | Phase 2 | Constipation |
| IDP-118 Vehicle Cream | Phase 2 | Psoriasis |
| Larsucosterol | Phase 3 | Hepatitis |
| Bisacodyl | Phase 3 | Chronic Idiopathic Constipation |
| IDP-121 Lotion | Phase 3 | Acne |
| SC MNTX | Phase 2 | Bowel Dysfunction |
| pradefovir mesylate | Phase 2 | Hepatitis B, Chronic |
| Low Dose Rifaximin ER | Phase 2 | Sickle Cell Disease |
| open-label rifaximin | Phase 3 | Irritable Bowel Syndrome With Diarrhea |
| Plecanatide | Phase 3 | Chronic Idiopathic Constipation |
| 5 ASA, enemas, suppositories, corticosteroids | Phase 3 | Ulcerative Colitis |
| ACYC | Phase 3 | Acne |
| Retigabine | Phase 2 | Postherpetic Neuralgia |
| IDP-126 Gel | Phase 3 | Acne Vulgaris |
| SAN-300 0.5 mg/kg QW | Phase 2 | Rheumatoid Arthritis |
| IDP-118 Lotion | Phase 3 | Plaque Psoriasis |
| IDP-124 Lotion | Phase 3 | Atopic Dermatitis |
| IDP-124 Vehicle Lotion | Phase 3 | Atopic Dermatitis |
Price & technical context
3-month
-19.0%
6-month
-22.1%
12-month
-33.7%
52-wk range
$4.43–$8.34
vs 50-day MA
-9.3%
vs 200-day MA
-22.7%
Realized vol
54.7%
Max drawdown
-55.8%
Daily closes through 2026-07-28. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BHC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.